CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for First Wave BioPharma Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

First Wave BioPharma Inc
777 Yamato Road, Suite 502
Phone: (561) 589-7020p:561 589-7020 BOCA RATON, FL  33431  United States Ticker: FWBIFWBI
Business Summary
First Wave BioPharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal (GI) diseases. It is focused on developing a therapeutic pipeline with multiple late-stage clinical programs built around three proprietary technologies: Latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides; the biologic Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency, and Capeserod, a selective 5-HT4 receptor partial agonist which the Company is developing as a gastroparesis therapeutic.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer James E.Sapirstein 61 3/13/2024 10/8/2019
President, Chief Operating Officer, Director JackSyage 69 3/13/2024 3/13/2024
Chief Financial Officer Sarah M.Romano 43 3/1/2022 3/1/2022
7 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
ImmunogenX, Inc. 1600 Dove Street Newport Beach CA United States

Business Names
Business Name
AZRX
AzurRx SAS
First Wave Bio, Inc.
FWBI
ImmunogenX, Inc.
ImmunogenX, LLC

General Information
Number of Employees: 15 (As of 3/27/2024)
Outstanding Shares: 2,025,199 (As of 3/27/2024)
Shareholders: 149
Stock Exchange: NASD
Federal Tax Id: 464993860
Email Address: info@azurrx.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, April 28, 2024